Subjects were recruited from DAISY, which is an ongoing prospective birth cohort study following genetically at-risk individuals for development of islet Aabs and clinical T1D (32). Written informed consent was obtained from each participant and guardian when the participant was less than 18 y of age, and the Colorado Multiple Institutional Review Board approved the study. Study visits occurred every 6 to 12 mo to collect peripheral blood for islet Aab measurements and ELISPOT assays. Additionally, glucose measurements were performed in the Aab+ cohort.

注意:以上内容是从某篇研究文章中自动提取的,可能无法正确显示。



Q&A
请登录并在线提交您的问题
您的问题将发布在Bio-101网站上。我们会将您的问题发送给本研究方案的作者和具有相关研究经验的Bio-protocol成员。我们将通过您的Bio-protocol帐户绑定邮箱进行消息通知。